Yes, terbutaline can cause hypokalemia
Terbutaline, as a β2-adrenergic agonist, causes hypokalemia through intracellular potassium shifting, and this effect is well-documented in both FDA labeling and clinical guidelines. This is a recognized adverse effect that requires monitoring, particularly in patients at risk for cardiac complications.
Mechanism and Clinical Evidence
The FDA drug label explicitly states that "beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting" 1. This mechanism involves stimulation of Na-K-ATPase pumps, which drives potassium into cells rather than causing true total body potassium depletion.
Magnitude of Effect
The potassium-lowering effect is substantial and dose-dependent:
- Mean decrease of 0.9 mEq/L occurs within 30 minutes of intravenous administration, before significant changes in glucose or insulin 2
- Nadir potassium levels can reach 2.5 mEq/L after 4-6 hours of continuous infusion 2, 3
- Sequential subcutaneous doses produce maximum reductions of approximately 1.1 mEq/L from baseline 4
- In healthy volunteers, intravenous terbutaline decreased serum potassium from 4.17 mmol/L to a nadir of 3.32 mmol/L 3
Clinical Significance and Cardiovascular Risk
The hypokalemia induced by terbutaline has important cardiovascular implications:
QTc interval prolongation is directly associated with terbutaline-induced hypokalemia. Studies demonstrate QTc prolongation of up to 60% (from 358 ms to 456 ms), with the effect closely correlated to simultaneous potassium decreases 5. The QTc interval increased from 377 ms to 441 ms following sequential terbutaline dosing 4.
Multiple guidelines emphasize that both hypokalemia and hyperkalemia can adversely affect cardiac excitability and conduction and may lead to sudden death 6, 7, 8, 9. The ACC/AHA heart failure guidelines specifically note that activation of the sympathetic nervous system can lead to hypokalemia 7, 9.
Cardiac Arrhythmias
In women receiving terbutaline for preterm labor, 3 of 14 patients developed symptomatic cardiac arrhythmias at the lowest plasma potassium levels, compared to none in the control group 2. The 2023 International Consensus on Cardiopulmonary Resuscitation documents that multiple studies show decreases in serum potassium after short-acting β-agonist use, though typically mild (mean decrease 0.52-0.54 mmol/L) 10.
Important Clinical Considerations
Drug Interactions
The FDA label warns that hypokalemia from non-potassium sparing diuretics can be acutely worsened by beta-agonists, especially when recommended doses are exceeded 1. Caution is advised when co-administering terbutaline with loop or thiazide diuretics.
Protection in Severe Pre-existing Hypokalemia
Interestingly, research shows that in severe pre-existing hypokalemia (<2 mmol/L), there is protection against further terbutaline-induced potassium reduction 11. However, in moderate hypokalemia, terbutaline still causes significant further decreases. This protection is immediately abolished when potassium is normalized by KCl infusion 11.
Monitoring Recommendations
Based on heart failure guidelines, serum potassium concentrations should be targeted in the 4.0 to 5.0 mEq/L range 6, 7, 8, 9. Even modest decreases in serum potassium can increase risks when using digitalis and antiarrhythmic drugs 7, 8.
Practical Management
Monitor serum potassium before and during terbutaline therapy, particularly with:
- Concurrent diuretic use
- Pre-existing cardiac disease
- Patients on digitalis or antiarrhythmic medications
- Sequential or high-dose administration
Avoid excessive dosing beyond recommended amounts, as the potassium-lowering effect is dose-dependent
Consider ECG monitoring in high-risk patients, as QTc prolongation correlates with hypokalemia severity
Potassium supplementation may be necessary in some patients, though correction of potassium deficits may also require magnesium supplementation 7, 9
The hypokalemia is typically transient and results from intracellular shifting rather than total body potassium depletion, but the cardiovascular consequences can be clinically significant, particularly in vulnerable populations.